AR034401A1 - Un compuesto derivado de la 4-pirimidinil-n-acil-l-fenilalanina, su uso, una composicion farmaceutica que lo comprende, un procedimiento para preparar una composicion farmaceutica, y un compuesto util como intermedio. - Google Patents
Un compuesto derivado de la 4-pirimidinil-n-acil-l-fenilalanina, su uso, una composicion farmaceutica que lo comprende, un procedimiento para preparar una composicion farmaceutica, y un compuesto util como intermedio.Info
- Publication number
- AR034401A1 AR034401A1 ARP000106415A ARP000106415A AR034401A1 AR 034401 A1 AR034401 A1 AR 034401A1 AR P000106415 A ARP000106415 A AR P000106415A AR P000106415 A ARP000106415 A AR P000106415A AR 034401 A1 AR034401 A1 AR 034401A1
- Authority
- AR
- Argentina
- Prior art keywords
- molecular weight
- low molecular
- weight alkyl
- alkyl
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 35
- 229910052739 hydrogen Inorganic materials 0.000 abstract 14
- 239000001257 hydrogen Substances 0.000 abstract 14
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 9
- 150000002431 hydrogen Chemical class 0.000 abstract 9
- 125000001589 carboacyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000003435 aroyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- -1 cyano, hydroxy Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto derivado de la 4-pirimidinil-N-acil-L-fenilalanina de fórmula (1), en la que R1 es un grupo de la fórmula (2) en la que: R22 y R23, con independencia entre sí, son hidrógeno, alquilo de bajo peso molecular, alcoxi de bajo peso molecular, cicloalquilo, arilo, arilalquilo, nitro, ciano, (alquilo de bajo peso molecular)-tio, (alquilo de bajo peso molecular)-sulfinilo, (alquilo de bajo peso molecular)-sulfonilo, alcanoílo de bajo peso molecular, halógeno o perfluor -(alquilo de bajo peso molecular), y por lo menos uno de R22 y R23 es diferente del hidrógeno, y R24 es hidrógeno, alquilo de bajo peso molecular, alcoxi de bajo peso molecular, arilo, nitro, ciano; (alquilo de bajo peso molecular)-sulfonilo o halógeno; o bien R1 es un grupo de la fórmula (2), que es un anillo heteroaromático de 5 o 6 eslabones, unido a través del átomo de carbono al carbonilo de la amida, dicho anillo contiene uno, dos o tres heteroátomos elegidos entre N, O y S y uno o dos átomos de dicho anillo están sustituidos con independencia entre sí por alquilo de bajo peso molecular, cicloalquilo, halógeno, ciano, perfluoralquilo o arilo y por lo menos uno de dichos átomos sustituidos está adyacente al átomo de carbono unido al carbonilo de la amida; o bien R1 es un grupo de la fórmula (3), que es un anillo de 3-7 eslabones de la fórmula (3), en la que R25 es alquilo de bajo peso molecular, alquenilo de bajo peso molecular sin sustituir o sustituido por flúor, o un grupo de la fórmula R26-(CH2)e-, R26 es arilo, heteroarilo, azido, ciano, hidroxi, alcoxi de bajo peso molecular, (alcoxi de bajo peso molecular)-carbonilo, alcanoílo de bajo peso molecular, (alquilo de bajo peso molecular)-tio, (alquilo de bajo peso molecular)-sulfonilo, (alquilo de bajo peso molecular)-sulfinilo, perfluor-(alcanoílo de bajo peso molecular), nitro, o bien R26 es un grupo de la fórmula -NR28R29, en la que R28 es hidrógeno o alquilo de bajo peso molecular; R29 es hidrógeno, alquilo de bajo peso molecular, (alcoxi de bajo peso molecular)-carbonilo, alcanoílo de bajo peso molecular, aroílo, perfluor-(alcanoílo de bajo peso molecular)-amino, (alquilo de bajo peso molecular)-sulfonilo, (alquilo de bajo peso molecular)-aminocarbonilo, arilaminocarbonilo; o bien R28 y R29 junto con el átomo de nitrógeno al que están unidos forman un anillo heterocíclico saturado de 4, 5 o 6 eslabones, que contiene un heteroátomo adicional, elegido entre O, S y N-R40; Q es -(CH2)fO-, -(CH2)fS-, -(CH2)fN(R27)-, -(CH2)f-; R27 es H, alquilo de bajo peso molecular, arilo, alcanoílo de bajo peso molecular, aroílo o (alcoxi de bajo peso molecular)-carbonilo; R40 es H, alquilo de bajo peso molecular, arilo, alcanoílo de bajo peso molecular, aroílo o (alcoxi de bajo peso molecular)-carbonilo, los átomos de carbono del anillo están sin sustituir o sustituidos por alquilo de bajo peso molecular o halógeno; ''e'' es un número entero de 0 a 4 y ''f'' es un número entero de 0 a 3; R2 es hidrógeno o alquilo de bajo peso molecular, alquilo de bajo peso molecular sustituido, arilalquilo o arilo; R3 es hidrógeno o alquilo de bajo peso molecular, alquilo de bajo peso molecular sustituido; arilalquilo o arilo; R4 es hidrógeno, halógeno, alquilo de bajo peso molecular, alquilo de bajo peso molecular sustituido (p. ej. perfluor-(alquilo de bajo peso molecular)), o arilo; R5 es hidrógeno, alquilo de bajo peso molecular, cloro o alcoxi de bajo peso molecular; R6 es hidrógeno, alquilo de bajo peso molecular, (alquilo de bajo peso molecular)-carboniloxi-(alquilo de bajo peso molecular), alquilo de bajo peso molecular sustituido o bien R6 es un grupo de la fórmula (4) en la que R32 es hidrógeno o alquilo de bajo peso molecular, R33 es hidrógeno, alquilo de bajo peso molecular, arilo; R34 es hidrógeno, alquilo de bajo peso molecular, ''h'' es un número entero de 0 a 2; ''g'' es un número entero de 0 a 2, la suma de h y g se sitúa entre 1 y 3; o bien R6 es un grupo de la fórmula (5), en la que R32, g y h tienen los significados recién definidos Q' es O, S, -(CH2)j- o un grupo de la fórmula N-R35; R35 es hidrógeno, alquilo de bajo peso molecular, alcanoílo de bajo peso molecular (alcoxi de bajo peso molecular)-carbonilo, ''j'' es el número 0, 1, o 2; o sus sales farmacéuticamente aceptables. Los compuestos de fórmula (1) son inhibidores de la unión entre la molécula VCAM-1 y las células de expresión del antígeno VLA-4 y, por consiguiente, son útiles para el tratamiento de enfermedades cuyos síntomas y/o lesiones pueden atribuirse a la unión de la molécula VCAM-1 con las células de expresión del VLA-4. Los compuestos de fórmula (1) son útiles por ejemplo en el tratamiento de artritis reumatoide, esclerosis múltiple, enfermedades inflamatoria intestinales y asma. También se describe el uso de los compuestos de fórmula (1) en la fabricación de un medicamento para el tratamiento de la artritis reumatoide, de la esclerosis múltiple, de las enfermedades inflamatorias intestinales y del asma. Composiciones farmacéuticas que los comprenden; un procedimiento para preparar una composición farmacéutica, y un compuesto útil como intermedio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16908999P | 1999-12-06 | 1999-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034401A1 true AR034401A1 (es) | 2004-02-25 |
Family
ID=22614222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000106415A AR034401A1 (es) | 1999-12-06 | 2000-12-04 | Un compuesto derivado de la 4-pirimidinil-n-acil-l-fenilalanina, su uso, una composicion farmaceutica que lo comprende, un procedimiento para preparar una composicion farmaceutica, y un compuesto util como intermedio. |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1237878B1 (es) |
| JP (1) | JP3824935B2 (es) |
| KR (1) | KR100522344B1 (es) |
| CN (1) | CN1218943C (es) |
| AR (1) | AR034401A1 (es) |
| AT (1) | ATE357433T1 (es) |
| AU (1) | AU783348B2 (es) |
| BR (1) | BR0016195A (es) |
| CA (1) | CA2392570C (es) |
| CO (1) | CO5080772A1 (es) |
| CY (1) | CY1106626T1 (es) |
| CZ (1) | CZ303435B6 (es) |
| DE (1) | DE60034061T2 (es) |
| DK (1) | DK1237878T3 (es) |
| EG (1) | EG24361A (es) |
| ES (1) | ES2282162T3 (es) |
| HK (1) | HK1054384B (es) |
| HR (1) | HRP20020468B1 (es) |
| HU (1) | HU229105B1 (es) |
| IL (2) | IL149617A0 (es) |
| JO (1) | JO2283B1 (es) |
| MA (1) | MA26850A1 (es) |
| MX (1) | MXPA02005564A (es) |
| MY (1) | MY126972A (es) |
| NO (1) | NO322866B1 (es) |
| NZ (1) | NZ518828A (es) |
| PE (1) | PE20010961A1 (es) |
| PL (1) | PL207160B1 (es) |
| PT (1) | PT1237878E (es) |
| RS (1) | RS50371B (es) |
| RU (1) | RU2266901C2 (es) |
| SI (1) | SI1237878T1 (es) |
| TW (1) | TWI256387B (es) |
| WO (1) | WO2001042225A2 (es) |
| ZA (1) | ZA200203533B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| ATE497385T1 (de) | 2000-08-18 | 2011-02-15 | Ajinomoto Kk | Neue phenylalanin-derivate |
| AR033765A1 (es) * | 2001-05-22 | 2004-01-07 | Syngenta Participations Ag | Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos. |
| WO2003053926A1 (en) | 2001-12-13 | 2003-07-03 | Ajinomoto Co.,Inc. | Novel phenylalanine derivative |
| EP1700850B1 (en) | 2003-12-22 | 2015-07-15 | Ajinomoto Co., Inc. | Phenylalanine derivative |
| US7618981B2 (en) * | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| CN101006097B (zh) * | 2004-08-16 | 2012-07-11 | 默沙东公司 | Vla-4拮抗剂 |
| JP4784224B2 (ja) | 2004-09-24 | 2011-10-05 | 味の素株式会社 | 糖鎖転移方法および糖鎖転移酵素 |
| EP2091916A2 (en) * | 2005-11-23 | 2009-08-26 | AstraZeneca AB | L-phenylalanine derivatives and their use as integrin antagonists |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| JP2009526032A (ja) * | 2006-02-09 | 2009-07-16 | アストラゼネカ アクチボラグ | 化合物 |
| ATE556061T1 (de) * | 2006-06-19 | 2012-05-15 | Toray Industries | Therapeutisches oder prophylaktisches mittel gegen multiple sklerose |
| DK2203431T3 (da) | 2007-09-17 | 2011-11-21 | Abbott Lab | Antiinfektiøse pyrimidiner og anvendelser heraf |
| TWI534137B (zh) * | 2007-09-17 | 2016-05-21 | 艾伯維巴哈馬有限公司 | 抗感染劑及其用途 |
| WO2009039135A1 (en) | 2007-09-17 | 2009-03-26 | Abbott Laboratories | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors |
| TWI448470B (zh) * | 2008-12-22 | 2014-08-11 | Icl Ip America Inc | 基於水互溶性溶劑的方法 |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| WO2012009699A2 (en) | 2010-07-16 | 2012-01-19 | Abbott Laboratories | Process for preparing antiviral compounds |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| BR112013001138A2 (pt) | 2010-07-16 | 2016-07-05 | Abbvie Inc | ligantes de fosfina para reações catalíticas |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US9447035B2 (en) * | 2012-01-27 | 2016-09-20 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 |
| CN104023751B (zh) * | 2012-01-27 | 2016-11-09 | 弗·哈夫曼-拉罗切有限公司 | 靶向递送至表达vla-4的细胞的整联蛋白拮抗剂结合物 |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| ES2778200T3 (es) | 2013-10-29 | 2020-08-10 | Ea Pharma Co Ltd | Derivado de sulfonamida y su uso medicinal |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
| CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH516578A (de) * | 1967-11-02 | 1971-12-15 | Bayer Ag | Verfahren zur Herstellung von heterocyclische Acylaminogruppen enthaltenden Arylsulfonylharnstoffen mit blutdrucksenkender Wirkung |
| EP1001764A4 (en) * | 1997-05-29 | 2005-08-24 | Merck & Co Inc | HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION |
| DE69833654T2 (de) * | 1997-05-29 | 2006-12-14 | Merck & Co., Inc. (A New Jersey Corp.) | Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren |
| ATE267801T1 (de) * | 1997-08-22 | 2004-06-15 | Hoffmann La Roche | N-alkanoylphenylalaninderivate |
| DE69821950T2 (de) * | 1997-08-22 | 2004-12-16 | F. Hoffmann-La Roche Ag | N-aroylphenylalaninderivate |
| CA2357781A1 (en) * | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
-
2000
- 2000-11-28 SI SI200030948T patent/SI1237878T1/sl unknown
- 2000-11-28 HU HU0204081A patent/HU229105B1/hu not_active IP Right Cessation
- 2000-11-28 JP JP2001543526A patent/JP3824935B2/ja not_active Expired - Fee Related
- 2000-11-28 MX MXPA02005564A patent/MXPA02005564A/es active IP Right Grant
- 2000-11-28 DK DK00989906T patent/DK1237878T3/da active
- 2000-11-28 BR BR0016195-0A patent/BR0016195A/pt active Search and Examination
- 2000-11-28 RS YUP-404/02A patent/RS50371B/sr unknown
- 2000-11-28 AT AT00989906T patent/ATE357433T1/de active
- 2000-11-28 EP EP00989906A patent/EP1237878B1/en not_active Expired - Lifetime
- 2000-11-28 RU RU2002117422/04A patent/RU2266901C2/ru not_active IP Right Cessation
- 2000-11-28 ES ES00989906T patent/ES2282162T3/es not_active Expired - Lifetime
- 2000-11-28 IL IL14961700A patent/IL149617A0/xx active IP Right Grant
- 2000-11-28 DE DE60034061T patent/DE60034061T2/de not_active Expired - Lifetime
- 2000-11-28 HR HR20020468A patent/HRP20020468B1/xx not_active IP Right Cessation
- 2000-11-28 CN CNB008167958A patent/CN1218943C/zh not_active Expired - Fee Related
- 2000-11-28 CA CA2392570A patent/CA2392570C/en not_active Expired - Fee Related
- 2000-11-28 PT PT00989906T patent/PT1237878E/pt unknown
- 2000-11-28 CZ CZ20022351A patent/CZ303435B6/cs not_active IP Right Cessation
- 2000-11-28 AU AU26696/01A patent/AU783348B2/en not_active Ceased
- 2000-11-28 WO PCT/EP2000/011884 patent/WO2001042225A2/en not_active Ceased
- 2000-11-28 KR KR10-2002-7007175A patent/KR100522344B1/ko not_active Expired - Fee Related
- 2000-11-28 NZ NZ518828A patent/NZ518828A/en not_active IP Right Cessation
- 2000-11-28 PL PL357601A patent/PL207160B1/pl unknown
- 2000-11-28 HK HK03106628.4A patent/HK1054384B/zh not_active IP Right Cessation
- 2000-11-29 JO JO2000190A patent/JO2283B1/en active
- 2000-12-03 EG EG20001502A patent/EG24361A/xx active
- 2000-12-04 MY MYPI20005690A patent/MY126972A/en unknown
- 2000-12-04 AR ARP000106415A patent/AR034401A1/es not_active Application Discontinuation
- 2000-12-05 PE PE2000001293A patent/PE20010961A1/es not_active Application Discontinuation
- 2000-12-05 TW TW089125890A patent/TWI256387B/zh not_active IP Right Cessation
- 2000-12-05 CO CO00092691A patent/CO5080772A1/es unknown
-
2002
- 2002-05-03 ZA ZA200203533A patent/ZA200203533B/en unknown
- 2002-05-13 IL IL149617A patent/IL149617A/en not_active IP Right Cessation
- 2002-06-04 NO NO20022633A patent/NO322866B1/no not_active IP Right Cessation
- 2002-06-05 MA MA26673A patent/MA26850A1/fr unknown
-
2007
- 2007-05-29 CY CY20071100715T patent/CY1106626T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031083A1 (es) | UN COMPUESTO DERIVADO DE LA 4-PIRIDINIL-N-ACIL-L-FENILALANINA, SU USO, UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE, UN PROCEDIMIENTO PARA FABRICAR DICHA COMPOSICION, Y UN COMPUESTO uTIL COMO INTERMEDIO. | |
| RU2015143000A (ru) | N-(4-(азаиндазол-6-ил)-фенил)-сульфонамиды и их применение в качестве лекарственных средств | |
| MXPA05008568A (es) | Nuevos compuestos anti-inflamatorios triazolo-piridinas. | |
| EA200500312A1 (ru) | Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз | |
| HUP0401982A2 (hu) | Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| CU23754B7 (es) | Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato. | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| DE602004001857D1 (de) | Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen | |
| MX2023009045A (es) | Derivados novedosos de pirimidin-2-il sulfonamida. | |
| EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение | |
| JP2011500586A5 (es) | ||
| RU2009118963A (ru) | Пурины в качестве ингибиторов ркс-тета | |
| DK1786790T3 (da) | Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser | |
| RU2314292C2 (ru) | Производные азетидина в качестве антагонистов ccr-3 рецептора | |
| MY139454A (en) | 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | |
| AR054863A1 (es) | DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA | |
| Halimehjani et al. | One-pot three-component route for the synthesis of S-trifluoromethyl dithiocarbamates using Togni’s reagent | |
| EA200600060A1 (ru) | Аминосульфонилзамещенные 4-(аминометил) пиперидинбензамиды в качестве 5нт-антагонистов | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| EA200401077A1 (ru) | 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b | |
| RU2205829C2 (ru) | Замещенное производное циклобутиламина, антибактериальный агент и фармацевтическая композиция на его основе | |
| MY140325A (en) | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| JP2012530075A5 (es) | ||
| HUP0100210A1 (hu) | 11 Béta-helyzetben szubsztituált új 19-nor-szteroidok, eljárás előállításukra, közbenső termékek és ilyen vegyületeket tartalmazó gyógyászati kompozíciók | |
| CY1107097T1 (el) | 5ht4-ανταγωνιστικα βενζαμιδια 4-( αμινομεθυλ) - πιπεριδινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |